Sentences with phrase «in tumor biomarkers»
Diet - induced changes in tumor growth occur in parallel with changes in tumor biomarkers such as proliferation and apoptosis which are associated with improved clinical outcomes in humans.
http://cancerres.aacrjournals.org/ Not exact matches
The focus of those hopes is the liquid biopsy: a test that could detect and analyze a solid tumor from biomarkers in the bloodstream or other easily sampled body fluids, such as saliva.
In the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the bodIn the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the bodin the body.
Many studies have shown serum TK1 to be a valuable cancer biomarker, but most previous assays have been enzyme - activity based and may underestimate its presence in solid tumors.
He is now fashioning the lab's multidots — tiny crystalline beads encapsulated in a special coating — into an actual product to detect multiple biomarkers on tumor cells.
«This finding,» Villanueva said «opens the door to developing new biomarkers and new therapeutic strategies exploiting these characteristics of exosomes in breast tumors, and other tumors such as ovarian and endometrial cancer among others.»
As not all cases of Barrett esophagus become malignant, it is important for the treating physician to know whether there are reliable indicators (so - called biomarkers) which allow the estimation of a tumor development in the still benign tissue.
The technology, developed by MIT professor and Howard Hughes Medical Institute investigator Sangeeta Bhatia, relies on nanoparticles that interact with tumor proteins called proteases, each of which can trigger release of hundreds of biomarkers that are then easily detectable in a patient's urine.
In an article titled, «Allergen Induced Pulmonary Inflammation Enhances Mammary Tumor Growth and Metastasis: Role of CH13L1,» featured on the cover of the current issue of the Journal of Leukocyte Biology, this new research suggests inflammation raises the level of a known biomarker of cancer, called «chitinase -3-like-1» or «CHI3L1,» in the inflamed tissue, which leads to increased metastasis and faster cancer growth in that tissuIn an article titled, «Allergen Induced Pulmonary Inflammation Enhances Mammary Tumor Growth and Metastasis: Role of CH13L1,» featured on the cover of the current issue of the Journal of Leukocyte Biology, this new research suggests inflammation raises the level of a known biomarker of cancer, called «chitinase -3-like-1» or «CHI3L1,» in the inflamed tissue, which leads to increased metastasis and faster cancer growth in that tissuin the inflamed tissue, which leads to increased metastasis and faster cancer growth in that tissuin that tissue.
A total of 67 biochemical features discriminated cancer from benign tumors in these samples, but only four specific metabolites could be considered as biomarkers for cancer: creatinine riboside, tryptophan, Nε, Nε, Nε - trimethyllysine, and 3 - methylhistidine.
«Despite the identification of circulating tumor cells (CTCs) and cell - free DNA (cfDNA) as biomarkers capable of providing clinically relevant information in cancer patients, at present their identification is not routinely used in clinical practice,» explains Silvia Morbelli, MD, PhD, of the IRCCS San Martino — IST National Cancer Research Institute and University of Genoa in Genoa, Italy.
«This finding suggests a novel therapeutic target to decrease invasion of tumor cells in patients and may also provide a novel biomarker that could help predict survival of patients with glioblastoma,» explained Israel.
A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
They found that in all nine cases, their data matched the outcomes seen in patients, as measured by clinical protein biomarkers found in the bloodstream, which are used by doctors to determine whether a drug is killing the tumor cells.
Another key finding was observing the inhibitor effect on tumor models with a gene PTEN deficiency as a biomarker — of huge interest because PTEN, a tumor suppressor, is known to be defective in as many as half of all advanced solid tumor cancers.
Importantly, the research team, funded by Cancer Research UK and the Medical Research Council, have also developed a biomarker test to identify SETD2 mutated tumors, something that can be used immediately in cancer diagnosis.
The researchers» next steps will involve expansion of the biomarkers identified in this study to other cancer types, especially breast cancer, due to the hormonal input that is a common factor in gynecologic tumors.
Confirmation of the biomarkers in other cancer types will facilitate further characterization and validation to provide mechanistic understanding of how and why these specific gene - targets become modulated to accentuate or inhibit tumor metastasis.
Baltimore, Md. (Embargoed until 12:30 pm EDT on Monday, June 8)-- A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.
The average tumor detected by ultrasound measures about five centimeters in diameter, and the biomarkers used in blood tests enable oncologists to detect tumors as small as one centimeter.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have discovered a peripheral biomarker in human blood serum that can be used to detect the presence and progress of glioblastoma brain tumors before and after treatment.
Our primary aim is to identify subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway, Metabolic - related genes) and / or immunologic (tumor - associated macrophage infiltration and / or programmed death ligand [PD - L1] expression) biomarkers in rNB.
Before he joined Moderna in 2013, Dr. Frederick was a Translational Research group leader at Aveo Oncology, focused on the generation of biomarkers for therapeutic response prediction, as well as avenues to modulate the tumor microenvironment for therapeutic benefit.
Aberrant expression of TUBB3 has also been found in various tumors of non-neural origin and can be used as a biomarker for cancer aggressiveness and a marker for the tendency to respond poorly to chemotherapy.
More information: MACC1 is an independent prognostic biomarker for survival in Klatskin tumor patients, Hepatology; 2015; 62:841 - 850
Early phase trials with anti-PD-L1 and anti-PD-1 antibodies have shown clinical activity in RCC and early biomarker assessment suggests PD - L1 tumor expression may influence response.
She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T cells as effector cells of the immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.
Blood Biomarkers Identified in Drug - Resistant Cancer Tumor Cells November 2016 While searching for a non-invasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with...
In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapIn the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapin selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapy.
The laboratory currently pursues four integrated research objectives: 1) Defining how dynamic regulation of adhesion and migration controls metastasis, 2) Identification and characterization of the metastatic cell populations within a primary tumor, 3) Experimental modeling of metastasis in a clinically relevant manner, and 4) clinical implementation of molecular markers of migration as biomarkers of tumor progression and metastasis.
Their work encompasses several strategies, including: developing FL - HCC animal models to characterize tumor - immune interactions, exploring if a mutated protein associated with FL - HCC could be targeted by immunotherapy, identifying immune checkpoints that could potentially serve as targets for immunotherapy as well as biomarkers for analyzing patients, and evaluating the effectiveness of immunotherapy strategies against FL - HCC patient samples in the lab.
This Institute is conducting ground - breaking research in the area of tumor biology and the development of cancer biomarkers using genomic and proteomic technologies in the hands of world - class scientists.
In a study involving 12 patients with bladder cancer, who also underwent prostate surgery as part of their treatment, she identified the ICOS molecule as the first immunologic marker identified in both tumor tissues and the systemic circulation that can be used as a biomarker for monitoring of anti-CTLA-4 treated patients as a possible marker of therapeutic activitIn a study involving 12 patients with bladder cancer, who also underwent prostate surgery as part of their treatment, she identified the ICOS molecule as the first immunologic marker identified in both tumor tissues and the systemic circulation that can be used as a biomarker for monitoring of anti-CTLA-4 treated patients as a possible marker of therapeutic activitin both tumor tissues and the systemic circulation that can be used as a biomarker for monitoring of anti-CTLA-4 treated patients as a possible marker of therapeutic activity.
He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action and resistance, and investigator - initiated clinical trials in breast cancer.
The clinical biostatistics team has strong connection with the Biometry department (Head A. Savignoni), the early phase clinical trial and precision medicine unit where patients are treated with drugs in development (Head C. Le Tourneau), the translational research department in particular the Circulating Tumor Biomarkers laboratory (Charlotte Proudhon), and of course the other teams of the U900.
In addition, our investigators have used epigenetic biomarkers to: develop screening tests for cancer; help guide surgeons in removing cancerous tumors; predict drug resistance; and, pinpoint more aggressive cancerIn addition, our investigators have used epigenetic biomarkers to: develop screening tests for cancer; help guide surgeons in removing cancerous tumors; predict drug resistance; and, pinpoint more aggressive cancerin removing cancerous tumors; predict drug resistance; and, pinpoint more aggressive cancers.
In 2016, another Berkeley Lab group found a potential new biomarker for early stages of tumor development in a wide variety of cancerIn 2016, another Berkeley Lab group found a potential new biomarker for early stages of tumor development in a wide variety of cancerin a wide variety of cancers.
Characterizing the molecular pathways regulating genomic stability at damaged replication forks in HR - deficient cancers will increase our understanding of the cellular response to replicative stress, and in the same time, potentially allow the identification of new predictors (biomarkers) of chemo - sensitivity / resistance in these tumors (Figure 2B).
Christina's research leverages genome - scale data, coupled with computational modeling and iterative experimentation in order to define the molecular determinants and dynamics of tumor progression and to develop predictive and prognostic biomarkers.
Our aim is to identify immunomodulatory mechanisms associated to the presence of the invading tumor in the LNs, and to discover biomarkers that could guide the design of patient - tailored immune therapies.
SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.
«Both total metabolic tumor volume (TMTV), computed on baseline PET, and end - of - induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor - burden follicular lymphoma,» reported lead author Anne Ségolène Cottereau, MD, from Cochin Hospital, René Descartes University, Paris, France, and colleagues.
Finally, analysis of tumors from clinical trials and cell line models will allow discovery of mechanisms of sensitivity and resistance to AR and PI3K inhibitors, as well as biomarkers that can be used in the development of new treatment regimens and selection of patients for future trials.
In one study on more than 3000 post-menopausal women, [23] increased magnesium intake was responsible for reducing three separate biomarkers for inflammation: CRP (C - reactive protein), TNF (tumor necrosis factor alpha), and IL6 (interleukin - 6).
Researchers followed a subset of 1,139 subjects and found that those with the greatest increases in urinary polyphenols had significantly lower levels of five different biomarkers of inflammation, such as adhesion molecules, interleukin, tumor necrosis factor alpha, and monocyte chemotactic protein.
Another study found a reduction in the inflammatory biomarkers human soluble tumor necrosis factor - α, interleukin - 6, C - reactive protein, and soluble intercellular adhesion molecule - 1 (61).
The methylome in DLBCL is a tumor landscape to be mined for novel early detection biomarkers, therapeutic drug targets, and additional understanding of carcinogenesis.
Alison's residency project, Effects of Resuscitative Fluid Therapy on Cardiac Biomarkers was accepted for publication and her article entitled, Intranasal Mast Cell Tumor in the Dog: A Case Series, has been published in the Canadian Veterinary Journal.